Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice.
Level 5 - mechanism / opinion, no new human data
Animal research (BALB/c mice)
PubMed 37243266 · doi:10.3390/v15051180
What was done
BALB/c mice were immunized with two Modified Vaccinia virus Ankara (MVA)-based COVID-19 candidate vaccines (MVA-SARS-2-S and MVA-SARS-2-ST) using either a 21-day (short-interval) or 56-day (long-interval) prime-boost schedule. Investigators evaluated spike-specific CD8 T-cell responses, total spike- and S2-specific IgG binding antibodies, S1- and receptor-binding domain (RBD)-specific antibodies, and SARS-CoV-2 neutralizing antibody titers.
What was found
The abstract reports no numerical values, confidence intervals, or exact p-values. Descriptively, both the 21-day and 56-day intervals elicited robust CD8 T-cell responses and comparable total S- and S2-specific IgG binding antibody levels with no significant differences between schedules. However, MVA-SARS-2-ST consistently induced higher levels of S1-, RBD-, and SARS-CoV-2 neutralizing antibodies compared to MVA-SARS-2-S across both vaccination protocols.
Why it matters
This study shows that extending the prime-boost interval from 3 to 8 weeks does not alter immunogenicity for these MVA-vectored vaccine candidates in mice, while identifying MVA-SARS-2-ST as the construct that elicits superior neutralizing antibody responses.
Limits
The study is restricted to a murine model, which the authors note may not capture interval-dependent differences seen in humans. The abstract omits sample sizes, exact titer measurements, statistical effect sizes, and live viral challenge protection outcomes.
Cited by
- supports In mouse immunization experiments, modifying the vaccine administration schedule can still achieve equivalent immune protection.